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ABSTRACT 
 
Background: Breast cancer is the number 2 cancer in Indonesia after cervical cancer. Breast 
cancer increases every year. The formation of breast cancer is stimulated by various factors such as 
obesity and a history of family planning. In breast cancer there are three important receptors, 
namely estrogen (ER) receptors, progesterone receptors (PR), and HER-2/Neu. The purpose of this 
study was to determine the association of obesity and history of family planning with the estrogen 
hormone receptor (ER), progesterone hormone receptor (PR), and HER-2/Neu expression in 
breast cancer patients in the dr. Moewardi Hospital in Surakarta, Central Java.  
Subjects and Method: This was an analytic observational study carried out at Dr. Moewardi 
Hospital, Surakarta, Central Java. A sample of 117 pre- and post-menopausal women who 
performed examinations at the oncology surgical clinic at Dr. Moewardi hospital, Surakarta was 
selected by total sampling. The dependent variables were estrogen and progesterone receptors and 
HER-2/Neu expressions. The independent variables were obesity and history of contraceptive 
method. Data was obtained from medical record and analyzed by a multiple logistic regression. 
Results: Obesity (OR= 0.29; 95% CI= 0.13 to 0.68; p= 0.004) reduced estrogen hormone 
receptors and it was statistically significant. History of contraceptive method (OR= 1.18; 95% CI= 
0.55 to 2.52; p= 0.680) increased estrogen hormone receptors but it was not statistically signi-
ficant. Obesity (OR=0.41; 95% CI= 0.18 to 0.96; p= 0.040) and history of contraceptive method 
(OR= 0.41; 95% CI= 0.19 to 0.88; p= 0.022) reduced progesterone hormone receptors. Obesity and 
history of contraceptive method increased Her-2/Neu expression. 
Conclusion: Obesity reduces estrogen hormone receptors. History of contraceptive method 
increases estrogen hormone receptors. Obesity and history of contraceptive method reduce pro-
gesterone hormone receptors. Obesity and history of contraceptive method increase Her-2/Neu 
expression. 
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BACKGROUND 
Cancer was one of the causes of death 
throughout the world. WHO data in 2012 
showed that around 8.2 million deaths were 
caused by cancer. In Indonesia, cancer was 
the number 2 cause of death in the world by 
13% after cardiovascular disease (RI Minis-
try of Health, 2015). In general, breast 
cancer attacked women, the possibility of 
breast cancer in men was very small, which 
was 1: 1000 (Mulyani, 2013). 
Factors at risk of increasing breast 
cancer were age, genetics, alcohol con-
sumption, smoking, lack of activity, history 
of family planning, estrogen hormones, and 
obesity (Kresnawan, 2012). Increased body 
weight or Body Mass Index (BMI) can 
increase the risk of breast, colon, prostate, 
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endo-metrium, kidney, and gall bladder 
cancers (Hamdy et al., 2013). Obesity 
factors can increase the risk of cancer by 
30% (Kresnawan,  2012). 
The use of hormonal contraception 
can lead to increased exposure to estrogen 
and progesterone hormones which can 
cause cell proliferation in the breast glands 
and inhibition of the apoptotic process so 
that it increased the risk of breast cancer 
(Nissa et al., 2017). 
A study by Soroush et al. (2016), 
stated that more than 4 years of pill use of 
hormonal contraception can increase breast 
cancer risk by 1.52 times. 
Estrogen was thought to increase 
breast cancer risk factors. In breast tissue, 
estrogen would stimulate growth and 
differentiation of the epithelium, induce 
mitotic activity of cells, stimulate growth of 
connective tissue and fat deposits in the 
breast. High estrogen levels were very 
influential on cancer growth in a person's 
breast (Guyton and Hall, 2008). 
Breast cancer has estrogen, progeste-
rone, and HER-2 hormone receptors. Posi-
tive hormone receptors in breast cancer 
patients represent the majority of breast 
cancers in the world. About 60% to 75% of 
women with breast cancer with estrogen 
positive receptors (ER +) and 65% of these 
cancers also have positive progesterone 
receptors (PR+) (Macmillan Cancer 
Support, 2011). 
Doctor Elysa, Public Relations 
Department of the Dr Moewardi Hospital 
reported, that there were over 500 cancer 
patients at Dr Moewardi Hospital every 
month. The highest were cervical cancer 
and breast cancer. The number was high 
and the increase reached 50% (Daryono, 
2016). Data from Dr. Moewardi Hospital, 
reported the number of breast cancer cases 
in 2014, namely, total hospitalization of 
3,583 patients and 9,909 of outpatients, 
while in 2015 the number of hospitalized 
patients increased to 4,596 patients and 
13,221 outpatients. 
 
SUBJECTS AND METHOD 
1. Study Design 
This study was an observational analytic 
conducted in the Surgical Oncology Section, 
Dr. Moewardi, Surakarta, Central Java.  
2. Population and Sample 
A sample of 117 pre- and post-menopausal 
women who performed examinations at the 
oncology surgical clinic at dr. Moewardi 
hospital, Surakarta, Central Java, was 
selected by purposive sampling. The inclu-
sion criteria were pre and post-menopausal 
cancer patients at the Poly Surgical Onco-
logy, and patients with no liver and/or 
kidney disorders. Exclusion criteria were 
incomplete medical records of breast cancer 
patients.  
3. Study Variable 
Dependent variables were estrogen and 
progesterone receptors and expression of 
HER-2/Neu. The independent variables 
were obesity and family history. 
4. Study Instruments 
Data on body weight, height, and results of 
hormone receptor and Her-2/Neu exami-
nation with Immunohistochemistry (CPI) 
of breast tissue biopsy were obtained from 
medical records at Dr. Moewardi hospital, 
Surakarta. 
5. Data Analysis  
Analysis of data was using multiple logistic 
regression analysis. 
 
RESULTS 
The majority of patients with breast cancer 
after menopause (54.7%), have low educa-
tion (41% graduated from elementary 
school), housewives (72.6%), obesity 
(56.4%), hormonal contraception (70.9%), 
estrogen hormonal receptor of positive 
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status (56.4%), positive progesterone hor-
mone receptor status (52.1%),  
Her-2/ positive Neu receptor hormonal 
status (50.4%). 
Table 1. The results of the logistic regression analysis of the relationship of 
obesity and history of family planning with the estrogen hormone receptor 
Dependent Variables OR 
CI 95% 
p 
Lower limit Upper limit 
Obesity 0.29 0.13 0.68 0.004 
History of FP 1.18 0.55 2.52 0.680 
P value Reg. Log. = 0.012 
Nagelkerke R-Square = 9.8% 
Hosmer and Lemesshow Test Chi Square 2.07 
p= 0.355 
 
Table 1 showed the results of the logistic 
regression analysis of the relationship of 
obesity and history of family planning to 
the estrogen hormone receptor. Table 1 
showed that obesity (OR = 0.29; 95% CI = 
0.13 to 0.68; p = 0.004) decreased estrogen 
hormone receptors and it was statistically 
significant. Family planning history (OR = 
1.18; 95% CI = 0.55 to 2.52; p = 0.680) 
increased estrogen hormone receptors but 
it was not statistically significant.  
Table 2.The results of the logistic regression analysis of the relationship of 
obesity and history of family planning with progesterone hormone receptors 
Dependent Variables OR 
CI 95% p 
Lower limit Upper limit 
Obesity 0.41 0.18 0.96 0.040 
History of FP 0.41 0.19 0.88 0.022 
p value Reg. Log.  = 0.010 
Nagelkerke R-Square = 10% 
Hosmer and Lemesshow Test Chi Square= 0.049 
p= 0.976 
 
Table 2 showed the results of the 
logistic regression analysis of the relation-
ship of obesity and history of family 
planning to the progesterone hormone 
receptor. Table 2 showed that obesity (OR = 
0.41; 95% CI = 0.18 to 0.96; p = 0.040) and 
family history (OR = 0.41; 95% CI = 0.19 to 
0.88; p= 0.022) decreased the progesterone 
hormone receptor. 
Table 3.The results of the logistic regression analysis of the relationship of 
obesity and family history to the expression of HER-2 / Neu 
Dependent Variables OR 
95% CI  
p 
Lower limit Upper limit 
Obesity 1.16 0.52 2.59 0.710 
History of contraceptive method 1.19 0.58 2.47 0.635 
P value Reg. Log.  = 0.841 
Nagelkerke R-Square= 4% 
Hosmer and Lemesshow Test Chi Square= 1.26 
p= 0.532 
 
Table 3 showed the results of the logistic 
regression analysis of the relationship of 
obesity and history of family planning to 
the expression of HER-2/Neu. Table 3 
showed that Obesity (OR= 1.16; 95% CI= 
0.52 to 2.59; p= 0.710) and family history 
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(OR= 1.19; 95% CI= 0.58 to 2.47; p= 0.635) 
increased Her-2/Neu expression but it was 
statistically insignificant. 
 
DISCUSSION 
The results showed the percentage of 
women suffering from breast cancer was 
higher at postmenopausal age (54.7%). This 
was consistent with the theory which stated 
that post-menopausal women have a higher 
risk of breast cancer than premenopausal 
women due to estrogen levels in the blood 
(Sastrawinata, 2007). The results of this 
study were in accordance with the research 
of Rianti and Emy et al., (2012), which 
stated that women aged> 50 years old were 
5.8 times more likely to develop breast 
cancer than women <50 years old.Breast 
cancer begins to develop rapidly at the age 
of 40-49 years old before women enter the 
age of 50 years old and above. The risk of 
breast cancer developed up to the age of 50 
years old with an odds ratio of 1 in 50 
women. The possibility of developing breast 
cancer increased with age, and more than 
75% of breast cancers were diagnosed in 
women aged 40 years old and over. Breast 
cancer was rare in women under 30 years 
old (Lincoln and Wilensky, 2008). 
The results also showed that most 
cancer patients were hormonal FP 
acceptors (70.9%). This result was in line 
with the research of Nissa PAE et al. (2017), 
which stated that the use of hormonal FP 
can cause the risk of breast cancer. The 
composition of the progestin injection 
consists of 150 mg of Medroxy progesterone 
Asetate and 200 mg of Depot Norestis-
terone Enantat. With composition and 
prolonged use it would cause the risk of 
breast cancer (Saifuddin et al., 2003). 
The other result was that breast 
cancer sufferers were mostly obese (56.4%). 
After menopause, fat tissue was the most 
important source of estrogen, where 
estrogen levels in postmenopausal women 
were higher by 50 to 100 percent compared 
to women of normal/ideal weight. Fat 
women have higher estrogen levels com-
pared to thin women due to increased peri-
pheral aromatization. This was related to 
SHBG levels, where a decrease in SHBG in 
obesity would increase the bioavailability of 
circulating estradiol, so obese women have 
a relatively higher risk of facing breast 
cancer (Lorincz and Sukumar, 2006). 
The results of this study were consist-
ent with the research of Green et al., (2012), 
which stated that obesity breast cancer 
patients have a strong relationship with ER 
(+) expression compared to ER (-) express-
ion. Obesity factors may have a significant 
role in ER expression and can have an 
effect on the progression and proliferation 
of breast cancer cells. 
The results of this study were in line 
with the research of Widiasari E (2016), 
which stated that the use of injection of 
Depot-Medroxy-progesterone Acetate 
(DMPA) has no significant relationship 
with the increase in estradiol levels. The 
results of Setiowati et al., (2016), suggested 
that there was a meaningful relationship 
between the use of hormonal family plann-
ing and the incidence of breast cancer. The 
consumption of estrogen from the outside 
until now was suspected of increasing the 
risk of breast cancer. The commonly used 
hormone combination pill was still con-
sidered safe and did not increase the risk of 
breast cancer. 
Users of hormonal contraception 
showed an increased risk of breast cancer, 
compared to those who did not use it. But 
the incidence of cancer was not only caused 
by the use of birth control pills. Many other 
influential factors include; obesity, prema-
ture menstruation, history of breast abnor-
malities, family history of breast cancer, 
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and not being physically active (Anakku, 
2014). 
Obesity which was associated with an 
increased increase in estrogen in human 
mammary epithelial cells (HMECs) 
increased the risk of breast cancer. The 
results of this study indicated that there 
was a significant relationship between obe-
sity and a history of family planning with 
progesterone hormone receptors in breast 
cancer patients. The results of this study 
were not in line with Rahmawati (2016) 
who stated that the use of hormonal contra-
ception did not correlate with the express-
ion of immunochemistry of progesterone 
and estrogen receptors. Women with BMI> 
30 during adulthood have a 3-fold relative 
risk of developing tumors with ER + PR +. 
In addition to receptor status that has a risk 
of breast cancer, age at first birth, post-
menopausal obesity, and estrogen-proges-
tin hormone therapy were stronger risk 
factors for positive-receptor breast cancer 
(Rosenberget al., 2006; Lordet al., 2008). 
The patient was said to have positive 
HER-2 if a large number of HER-2 tumors 
are found. Positive HER-2 cancer was 
known as an aggressive form of breast 
cancer and has a worse estimate of disease 
than patients with negative HER-2. It was 
estimated that one in four to five patients 
with late stage breast cancer has positive 
HER-2 (Seidenfeld et al., 2008; Slamon et 
al., 1989; Thor et al., 1989). Amplification 
of the Her-2/neu gene was another prog-
nostic and predictive factor for breast 
cancer. About 20% of breast cancer patients 
have amplification of the Her 2 Neu gene 
which lead to overexpression glycogen 
protein (Burstein et al, 2008). 
The results of this study indicated that 
obesity and history of family planning 
increase HER-2/Neu expression in breast 
cancer patients but it was not statistically 
significant.  
The difference between the results of 
the study and the theoretical basis can 
occur, presumably because there was no 
increase in proliferation and metastasis due 
to over expression or amplification of the 
HER-2 gene. In addition, because it was 
estimated that amplification only occurred 
around 20-30% in breast cancer cases. Over 
HER-2 gene expression was more common 
in high-grade breast cancer (abnormally 
fast cell growth) or advanced clinical stage 
compared to low grade (slow abnormal cell 
growth) or low clinical stage (Tang et al., 
2006). 
The incompatibility of the results of 
the research with the theory in this study 
was because the sample of breast cancer 
patients with TNM clinical stage data was 
not only from advanced data in all receptor 
status subgroups, there was a possibility 
that HER-2 gene amplification which would 
result in proliferation and metastasis 
cancer cells. This result was supported by a 
theoretical basis for the imbalance of the 
hormones progesterone and estrogen which 
were actually used for hormonal 
contraceptives. 
There were two theories that discuss 
how estrogen and progesterone cause 
breast cancer, namely the risk of cell muta-
tion when division increased because cell 
proliferation by increasing estrogen and 
progesterone also increased (Prawirohardjo 
S, 2011) and estrogen and progesterone 
stimulate the growth of breast cancer peak 
cells (Kresno, 2012). 
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